Listing of Claims:

The following listing of claims replaces all prior versions and listings of claims in the application. Additions are indicated by underlining and deletions are indicated by strikethrough.

1. – 72. (Canceled)

73.   (Original) A method for modifying the effector function of an antibody, the method comprising:

(a)   providing at least one nucleic acid derived from at least one immunoglobulin heavy chain constant region;

(b)   recombining the at least one nucleic acid to produce a library of recombinant immunoglobulin constant region nucleic acids;

(c)   optionally repeating the recombination process of steps (a) and (b) one or more times;

(d)   selecting at least one recombinant immunoglobulin constant region nucleic acid encoding a Fc region with a desired property;

(e)   optionally repeating steps (a) through (d) one or more time until the Fc region has acquired a desired property.

74.- 76. (Canceled)

77.   (Original) The method of claim 73, comprising selecting the at least one recombinant immunoglobulin constant region nucleic acid *in vitro*.

78.   (Original) The method of claim 77, wherein the selecting is performed by an assay selected from: Fc receptor binding, complement fixation, complement mediated cell lysis, and activation of a proteolytic complement component, and flow cytometry.

79.   (Original) The method of claim 73, comprising selecting selecting the at least one recombinant immunoglobulin constant region nucleic acid *in vivo*.

80.   (Original) The method of claim 79, wherein the selecting is performed by an assay selected from: serum half-life, pathogenic challenge, toxin neutralization, small molecule clearance, half-life extension of a protein pharmaceutical, and tumorigenesis.

81.   (Original) The method of claim 73, wherein the desired property is selected from among: Kd of Fc receptor binding, Kd of C1q binding, and activation of C1q proteolytic activity.

82. – 88. (Canceled)